Literature DB >> 12502802

The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity.

Michael Thomson1, Michelina Nascimbeni, Michael B Havert, Marian Major, Sophia Gonzales, Harvey Alter, Stephen M Feinstone, Krishna K Murthy, Barbara Rehermann, T Jake Liang.   

Abstract

Clearance of hepatitis C virus (HCV) infection in humans and chimpanzees is thought to be associated with the induction of strong T-cell responses. We studied four chimpanzees infected with HCV derived from an infectious full-length HCV genotype 1b cDNA. Two of the chimpanzees cleared the infection to undetectable levels for more than 12 months of follow-up; the other two became persistently infected. Detailed analyses of HCV-specific immune responses were performed during the courses of infection in these chimpanzees. Only weak and transient T helper responses were detected during the acute phase in all four chimpanzees. A comparison of the frequency of gamma interferon (IFN-gamma)-producing CD4(+) and CD8(+) T cells in peripheral blood by ELISpot assay did not reveal any correlation between viral clearance and T-cell responses. In addition, analyses of IFN-gamma, IFN-alpha, and interleukin-4 mRNA levels in liver biopsies, presumably indicative of intrahepatic T-cell responses, revealed no distinct pattern in these chimpanzees with respect to infection outcome. The present study suggests that the outcome of HCV infection in chimpanzees is not necessarily attributable to HCV sequence variation and that chimpanzees may recover from HCV infection by mechanisms other than the induction of readily detectable HCV-specific T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502802      PMCID: PMC140840          DOI: 10.1128/jvi.77.2.862-870.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Hepatitis C virus replication in mice with chimeric human livers.

Authors:  D F Mercer; D E Schiller; J F Elliott; D N Douglas; C Hao; A Rinfret; W R Addison; K P Fischer; T A Churchill; J R Lakey; D L Tyrrell; N M Kneteman
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

3.  Infectious cDNA clone of the hepatitis C virus genotype 1 prototype sequence.

Authors:  Robert E Lanford; Helen Lee; Deborah Chavez; Bernadette Guerra; Kathleen M Brasky
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

4.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

5.  Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies.

Authors:  Eishiro Mizukoshi; Michelina Nascimbeni; Joshua B Blaustein; Kathleen Mihalik; Charles M Rice; T Jake Liang; Stephen M Feinstone; Barbara Rehermann
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA.

Authors:  M Honda; E A Brown; S M Lemon
Journal:  RNA       Date:  1996-10       Impact factor: 4.942

7.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.

Authors:  A L Erickson; Y Kimura; S Igarashi; J Eichelberger; M Houghton; J Sidney; D McKinney; A Sette; A L Hughes; C M Walker
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

8.  Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus.

Authors:  M Thomson; M Nascimbeni; S Gonzales; K K Murthy; B Rehermann; T J Liang
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

9.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees.

Authors:  H Kowalski; A L Erickson; S Cooper; J D Domena; P Parham; C M Walker
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

View more
  28 in total

1.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Authors:  Harel Dahari; Stephen M Feinstone; Marian E Major
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

2.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

3.  Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.

Authors:  Sayed F Abdelwahab; Zainab Zakaria; Maha Sobhy; Eman Rewisha; Mohamed A Mahmoud; Mahmoud A Amer; Mariarosaria Del Sorbo; Stefania Capone; Alfredo Nicosia; Antonella Folgori; Mohamed Hashem; Samer S El-Kamary
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

4.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.

Authors:  Takaji Wakita; Thomas Pietschmann; Takanobu Kato; Tomoko Date; Michiko Miyamoto; Zijiang Zhao; Krishna Murthy; Anja Habermann; Hans-Georg Kräusslich; Masashi Mizokami; Ralf Bartenschlager; T Jake Liang
Journal:  Nat Med       Date:  2005-06-12       Impact factor: 53.440

5.  Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Authors:  Judith M Gottwein; Troels K H Scheel; Benoit Callendret; Yi-Ping Li; Heather B Eccleston; Ronald E Engle; Sugantha Govindarajan; William Satterfield; Robert H Purcell; Christopher M Walker; Jens Bukh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

Review 6.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

7.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

8.  Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.

Authors:  Gamal A Elmowalid; Ming Qiao; Sook-Hyang Jeong; Brian B Borg; Thomas F Baumert; Ronda K Sapp; Zongyi Hu; Krishna Murthy; T Jake Liang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-07       Impact factor: 11.205

Review 9.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.

Authors:  C Rollier; E Depla; J A R Drexhage; E J Verschoor; B E Verstrepen; A Fatmi; C Brinster; A Fournillier; J A Whelan; M Whelan; D Jacobs; G Maertens; G Inchauspé; J L Heeney
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.